APA (7th ed.) Citation

Serresi, M., Siteur, B., Hulsman, D., Company, C., Schmitt, M. J., Lieftink, C., . . . Gargiulo, G. (2018). Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. The Journal of experimental medicine, 215(12), 3115. https://doi.org/10.1084/jem.20180801

Chicago Style (17th ed.) Citation

Serresi, Michela, et al. "Ezh2 Inhibition in Kras-driven Lung Cancer Amplifies Inflammation and Associated Vulnerabilities." The Journal of Experimental Medicine 215, no. 12 (2018): 3115. https://doi.org/10.1084/jem.20180801.

MLA (9th ed.) Citation

Serresi, Michela, et al. "Ezh2 Inhibition in Kras-driven Lung Cancer Amplifies Inflammation and Associated Vulnerabilities." The Journal of Experimental Medicine, vol. 215, no. 12, 2018, p. 3115, https://doi.org/10.1084/jem.20180801.